Showing 4591-4600 of 5957 results for "".
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmissionhttps://modernod.com/news/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission/2480621/Eyenovia announced that the company successfully completed a meeting with the FDA related to the refiling of the NDA for MydCombi. On October 22, 2021, Eyenovia received a complete response letter (CRL) from the FDA stating that MydCombi, the co
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director
- Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Modelhttps://modernod.com/news/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/2480611/Skye Bioscience announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining greater function of the eye’s retinal ganglion cells (RGCs) versus vehicle control. RGCs are cells
- GlobalData: Glaucoma Market to Grow to $3.5 Billion by 2030, Driven by Launch of New Pipeline Productshttps://modernod.com/news/globaldata-glaucoma-market-to-grow-to-35-billion-by-2030-driven-by-launch-of-new-pipeline-products/2480609/Steady growth is expected for the glaucoma market across the seven major markets* from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. According to the leading data and analytics company’s latest re
- FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Wet AMD and DMEhttps://modernod.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved inj
- Nanodropper and Lumata Health Launch Partnership Aimed at Improving Patient Carehttps://modernod.com/news/nanodropper-and-lumata-health-launch-partnership-aimed-at-improving-patient-care/2480600/Nanodropper recently announced a partnership with Lumata Health, which includes the launch of a pilot program bringing the Nanodropper Adaptor device to Lumata Health network patients across the United States. Lumata Health is a tech-enabled health care service company fo
- Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseaseshttps://modernod.com/news/kriya-licenses-next-generation-complement-targeted-gene-therapies-for-the-treatment-of-geographic-atrophy-and-other-ocular-diseases/2480593/Kriya Therapeutics announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases. "This partne
- NIH Study Classifies Vision Loss and Retinal Changes in Stargardt Diseasehttps://modernod.com/news/nih-study-classifies-vision-loss-and-retinal-changes-in-stargardt-disease/2480590/National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt. The method quantifies disease-related loss of light-sensing retina cells, yielding information for monitoring patients, understanding genetic causes of the disea
- 2022 President Robert E. Wiggins Jr., MD, MPH Takes the Academy’s Reinshttps://modernod.com/news/2022-president-robert-e-wiggins-jr-md-mph-takes-the-academys-reins/2480585/Medicine is a constantly developing industry—just ask 2022 Academy President Robert E. Wiggins Jr., MD, MPH. When his practice was acquired in the 1990s, Dr. Wiggins returned to school and obtained a masters degree in health care administration, turning Asheville Eye Associa